Common use of Disposition of Inventories of Products Clause in Contracts

Disposition of Inventories of Products. Following termination of this Agreement by CytomX pursuant to Section 8.3 or 8.4, ImmunoGen and its Affiliates and Sublicensees shall have the right to continue to sell their existing inventories of Licensed Product(s) that have received Regulatory Marketing Approval prior to such termination for a period [***] after the effective date of such termination or expiration and ImmunoGen shall pay any milestones and royalties payable in connection with such sales in accordance with Article 4 hereof.

Disposition of Inventories of Products. Following termination of this Agreement by CytomX ImmunoGen pursuant to Section 8.3 or 8.4, ImmunoGen CytomX and its Affiliates and Sublicensees shall have the right to continue to sell their existing inventories of Licensed Product(s) that have received Regulatory Marketing Approval prior to such termination for a period [***] after the effective date of such termination or expiration and ImmunoGen CytomX shall pay any milestones and royalties payable in connection with such sales in accordance with Article 4 hereof.

Disposition of Inventories of Products. Following termination of this Agreement by CytomX ImmunoGen pursuant to Section 8.3 or 8.4, ImmunoGen CytomX and its Affiliates and Sublicensees shall have the right to continue to sell their existing inventories of Licensed Product(s) that have received Regulatory Marketing Approval prior to such termination for a period [***] not to exceed six (6) months after the effective date of such termination or expiration and ImmunoGen CytomX shall pay any milestones and royalties payable in connection with such sales in accordance with Article 4 hereof.

Disposition of Inventories of Products. Following termination of this Agreement by CytomX pursuant to Section 8.3 or 8.4, ImmunoGen and its Affiliates and Sublicensees shall have the right to continue to sell their existing inventories of Licensed Product(s) that have received Regulatory Marketing Approval prior to such termination for a period [***] not to exceed six (6) months after the effective date of such termination or expiration and ImmunoGen shall pay any milestones and royalties payable in connection with such sales in accordance with Article 4 hereof.